[1] RAWLA P, SUNKARA T, BARSOUK A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors[J]. Prz Gastroenterol, 2019, 14(2): 89-103. [2] KALTENBACH T, ANDERSON J C, BURKE C A, et al. Endoscopic removal of colorectal lesions-recommendations by the US multi-society task force on colorectal cancer[J]. Gastroenterology, 2020, 158(4): 1095-1129. [3] MURATA M. Inflammation and cancer[J]. Environ Health Prev Med, 2018, 23(1): 50. [4] AL OBEED O A, ALKHAYAL K A, SHEIKH A A, et al. Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages[J]. World J Gastroenterol, 2014, 20(48): 18390-18396. [5] LI Q R, WU H L, CAO M M, et al. Colorectal cancer burden, trends and risk factors in China: a review and comparison with the United States[J]. Chung Kuo Yen Cheng Yen Chiu, 2022, 34(5): 483-495. [6] ZHANG L, CAO F, ZHANG G Y, et al. Trends in and predictions of colorectal cancer incidence and mortality in China from 1990 to 2025[J]. Front Oncol, 2019, 9: 98. [7] 于秀冰, 夏志坤, 丁保锋. 结直肠癌患者组织TNF-α、MCP-1表达水平与病理进展的相关性[J]. 临床和实验医学杂志, 2022, 21(5): 505-508. [8] 禹蓉, 董卫国, 田山, 等. 不同病理类型结直肠息肉癌变的临床研究进展[J]. 中国全科医学, 2023, 26(14): 1790-1794. [9] SHORT M, LAYTON M C, TEER B, et al. Colorectal cancer screening and surveillance[J]. American family physician, 2015, 91(2): 93-100. [10] LIEBERMAN D A, REX D K, WINAWER S J, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer[J]. Gastroenterology, 2012, 143(3): 844-857. [11] 龙华婧, 夏阳, 刘道利, 等. 血清TNF-α在结直肠癌患者中的临床价值研究[J]. 国际检验医学杂志, 2017, 38(10): 1319-1321. [12] STANILOV N, MITEVA L, DOBREVA Z, et al. Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha[J]. Biotechnol Biotechnol Equip, 2014, 28(5): 911-917. [13] LIU M, LEE D F, CHEN C T, et al. IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression[J]. Mol Cell, 2012, 45(2): 171-184. [14] YANG Z, JIANG X D, ZHANG Z H, et al. HDAC3-dependent transcriptional repression of FOXA2 regulates FTO/m6A/MYC signaling to contribute to the development of gastric cancer[J]. Cancer Gene Ther, 2021, 28(1/2): 141-155. [15] CAMOLOTTO S A, PATTABIRAMAN S, MOSBRUGER T L, et al. FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer[J]. Elife, 2018, 7: e38579. [16] SALEM M, O’BRIEN J A, BERNAUDO S, et al. miR-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway[J]. Cancer Res, 2018, 78(15): 4175-4190. [17] SONG Y, WASHINGTON M K, CRAWFORD H C. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer[J]. Cancer Res, 2010, 70(5): 2115-2125. [18] 彭好. Foxa2在结直肠息肉和结直肠癌中的表达及其意义[J]. 胃肠病学, 2019, 24(11): 655-659. [19] VAN DOORN S C, HAZEWINKEL Y, EAST J E, et al. Polyp morphology: an interobserver evaluation for the Paris classification among international experts[J]. Am J Gastroenterol, 2015, 110(1): 180-187. [20] WANG B L, LIU G W, DING L, et al. FOXA2 promotes the proliferation, migration and invasion, and epithelial mesenchymal transition in colon cancer[J]. Exp Ther Med, 2018, 16(1): 133-140. [21] DEBNATH P, HUIREM R S, DUTTA P, et al. Epithelial-mesenchymal transition and its transcription factors[J]. Biosci Rep, 2022, 42(1): BSR20211754. [22] LU W, KANG Y B. Epithelial-mesenchymal plasticity in cancer progression and metastasis[J]. Dev Cell, 2019, 49(3): 361-374. |